LUMIRABIO Opens Its Peptide and Nucleic Acid Drug Innovation Research Center
The center opened on September 20, bringing partners, management and the R&D team together to mark a new stage in research development.
Read articleLUMIRABIO JOURNAL
News & Insights
From our team and the exhibition floor to the science behind peptide development.
Latest stories
Company News
People, milestones and updates from LUMIRABIO.
Jinjiang Mayor Wang Xiaoyang Leads Official Delegation to LUMIRABIO for On-Site Visit and Strategic Exchange
The municipal delegation heard LUMIRABIO Chairman Cai Jinmiao present the company's end-to-end development and scale-up pathway, facilities and purification systems being developed in line with relevant GMP requirements, and plans for a future lights-out smart factory.
Read articleExhibitions & Events
Meet our team and revisit our industry events.
LUMIRABIO at CIBE Guangzhou 2026: A Look Back at Booth J08A
LUMIRABIO participated in the 71st China (Guangzhou) International Beauty Expo on 4–6 September 2026 at the China Import and Export Fair Complex. Our stand was located in Hall 5.2, Booth J08A. Our presentation focused on peptide materials, custom synthesis and opportunities for development collaboration.
Read article
LUMIRABIO at CPHI & PMEC Shenzhen 2026: Booth 9G75 Recap
LUMIRABIO exhibited at Hall 9, Booth 9G75 during CPHI & PMEC Shenzhen on 16–18 September 2026 at the Shenzhen Convention & Exhibition Center in Futian. The event has ended; qualified teams can continue a peptide API project discussion through our website.
Read article
LUMIRABIO at CPHI China 2026: Peptide API Conversations and Next Steps
At CPHI China 2026, LUMIRABIO discussed semaglutide-, tirzepatide- and retatrutide-related peptide programs with pharmaceutical, CMC, procurement and development teams. The most useful conversations moved quickly from product names to specifications, impurity profiles, batch evidence and market-specific feasibility.
Read articleIndustry Insights
Perspectives on peptide development, analysis and sourcing.
Your First Peptide Supplier Inquiry: What to Share Before the Technical File
Your first email to a prospective peptide supplier should contain only optional, already confirmed project details that are internally cleared for external disclosure, along with a clear note on which parameters are still to be confirmed or withheld pending a confidentiality arrangement.
Read article
Retatrutide Nonclinical Studies: Who Should Source the Test Material?
Before accepting a contract research organization's quotation, decide who will place the material order, who will assess the proposed material for the study, and who can approve a change. Those can be three different people. Having the CRO organize procurement may reduce coordination work, but it does not by itself settle the material's suitability or the responsibilities of the study team.
Read article
Peptide Testing Deliverables: Agree Reports, Files and Access Before Ordering
Before placing an external peptide-testing order, describe what your team needs to do with the delivery: read a conclusion, compare results across samples, review how a result was produced, or revisit the data later. Then name the files, supporting information, access conditions and responsible people needed for that task. A test name and a promise of “a report” leave these choices open.
Read article